Related references
Note: Only part of the references are listed.The Research Progress of Antiangiogenic Therapy, Immune Therapy and Tumor Microenvironment
Haoyue Hu et al.
FRONTIERS IN IMMUNOLOGY (2022)
EGFR-Mutated Non-Small Cell Lung Cancer and Resistance to Immunotherapy: Role of the Tumor Microenvironment
Clelia Madeddu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Immunophenotyping of pulmonary sarcomatoid carcinoma
Yu Ma et al.
FRONTIERS IN IMMUNOLOGY (2022)
The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma
Xiaoying Qian et al.
FRONTIERS IN IMMUNOLOGY (2022)
Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China
Xiangyu Zhang et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
The genomic and immunologic profiles of pure pulmonary sarcomatoid carcinoma in Chinese patients
Fei Zhou et al.
LUNG CANCER (2021)
Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC
Tianqing Chu et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Immune checkpoint inhibitors plus anlotinib versus anlotinib alone as third-line treatment in advanced non-small-cell lung cancer: a retrospective study
Wenjie Zhang et al.
FUTURE ONCOLOGY (2021)
Programmed death ligand-1 expression levels, clinicopathologic features, and survival in surgically resected sarcomatoid lung carcinoma
Yetkin Agackiran et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2021)
Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma
Charlotte Domblides et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Pulmonary Sarcomatoid Carcinoma: Experience From SEER Database and Shanghai Pulmonary Hospital
Liangdong Sun et al.
ANNALS OF THORACIC SURGERY (2020)
Relationship Between Programmed Death Receptor-Ligand 1 Expression and Response to Checkpoint Inhibitor Immunotherapy in Pulmonary Sarcomatoid Carcinoma: A Pooled Analysis
Nalan A. Babacan et al.
CLINICAL LUNG CANCER (2020)
anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells
Shaochuan Liu et al.
CELL DEATH & DISEASE (2020)
Outstanding clinical efficacy of PD-1/PD-L1 inhibitors for pulmonary pleomorphic carcinoma
Jiyun Lee et al.
EUROPEAN JOURNAL OF CANCER (2020)
Integrated molecular characterization reveals potential therapeutic strategies for pulmonary sarcomatoid carcinoma
Zhenlin Yang et al.
NATURE COMMUNICATIONS (2020)
PhaseIIstudy of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma:KCSG-LU16-07
Miso Kim et al.
THORACIC CANCER (2020)
Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment
Yuxiao Song et al.
FRONTIERS IN IMMUNOLOGY (2020)
Dramatic Response of Pulmonary Sarcomatoid Carcinoma to Nivolumab Combined with Anlotinib: A Case Report
Caibao Jin et al.
CASE REPORTS IN ONCOLOGY (2020)
Mutation landscape and tumor mutation burden analysis of Chinese patients with pulmonary sarcomatoid carcinomas
Xiaohong Liang et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2019)
Immune Checkpoint Blockade Is Associated With Durable Responses in Pulmonary Sarcomatoid Carcinoma
Vineeth Sukrithan et al.
CLINICAL LUNG CANCER (2019)
Pulmonary sarcomatoid carcinoma: an analysis of a rare cancer from the Surveillance, Epidemiology, and End Results database
Mohamed Rahouma et al.
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY (2018)
Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)
Baohui Han et al.
BRITISH JOURNAL OF CANCER (2018)
A clinical analysis of 114 cases of sarcomatoid carcinoma of the lung
Junna Hou et al.
CLINICAL AND EXPERIMENTAL MEDICINE (2018)
Sarcomatoid Carcinoma of the Lung: The Mayo Clinic Experience in 127 Patients
Kunlatida Maneenil et al.
CLINICAL LUNG CANCER (2018)
Anlotinib inhibits angiogenesis &ITvia&IT suppressing the activation of VEGFR2, PDGFRβ and FGFR1
Binyan Lin et al.
GENE (2018)
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Dal Fukurnura et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer The ALTER 0303 Phase 3 Randomized Clinical Trial
Baohui Han et al.
JAMA ONCOLOGY (2018)
Inter-relationship between PD-L1 expression and clinic-pathological features and driver gene mutations in pulmonary sarcomatoid carcinomas
Filippo Lococo et al.
LUNG CANCER (2017)
Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation
Elizabeth Allen et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Molecular classification of pulmonary sarcomatoid carcinomas suggests new therapeutic opportunities
N. Pecuchet et al.
ANNALS OF ONCOLOGY (2017)
Characteristics and Clinical Outcomes of Sarcomatoid Carcinoma of the Lung
Mony Ung et al.
CLINICAL LUNG CANCER (2016)
Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages
Thibault Vieira et al.
LUNG CANCER (2016)
Molecular characterization of pulmonary sarcomatoid carcinoma: analysis of 33 cases
Simone B. S. P. Terra et al.
MODERN PATHOLOGY (2016)
Pembrolizumab (Keytruda)
Gerry Kwok et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2016)
Blood vessel invasion is a major feature and a factor of poor prognosis in sarcomatoid carcinoma of the lung
Thibault Vieira et al.
LUNG CANCER (2014)
NF1 gene silencing induces upregulation of vascular endothelial growth factor expression in both Schwann and non-Schwann cells
Yasuhiro Kawachi et al.
EXPERIMENTAL DERMATOLOGY (2013)
Efficacy of First-Line Chemotherapy in Patients with Advanced Lung Sarcomatoid Carcinoma
Thibault Vieira et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
Share Paper
